Crewe Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Crewe Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30	Closed	-$1K	–	1252
2022 Q3	$1K	Buy	+30	New	+$860	﹤0.01%	1203

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Crewe Advisors's SWTX Position: Q4 2022 in Review

Crewe Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 30 shares — an estimated $1K sold.

Crewe Advisors first reported a position in SWTX in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

Crewe Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 30 SpringWorks Therapeutics shares in Q4 2022, an estimated $1K.
Crewe Advisors first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 1 quarter.
Crewe Advisors's SpringWorks Therapeutics position peaked at $1K in Q3 2022.
137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.